SL
LGND icon

Salomon & Ludwin’s Ligand Pharmaceuticals LGND Stock Holding History

Salomon & Ludwin’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.4K Hold
200
– – 0.01% 444
2026
Q1 		$39.9K Buy
200
+56
+39% +$11.1K ﹤0.01% 614
2025
Q4 		$27.7K Sell
144
-1
-0.7% -$192 ﹤0.01% 660
2025
Q3 		$26.2K Buy
+145
New +$21.6K ﹤0.01% 647

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Salomon & Ludwin's LGND Position: Q2 2026 in Review

Salomon & Ludwin held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 200 shares worth $62.4K. The position accounts for 0.01% of the portfolio, ranked #444.

Salomon & Ludwin first reported a position in LGND in Q3 2025 and has held it in 4 quarters since. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Salomon & Ludwin held 200 shares of Ligand Pharmaceuticals worth $62.4K as of Q2 2026.
  • Salomon & Ludwin left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up 0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #444 holding.
  • Salomon & Ludwin first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.